Announcements Trials
Browse Landscape

Phase

Phase 2 68Phase 3 42Phase 1 40Phase 1/2 36Phase NA 3Phase 4 2Phase EARLY_PHASE1 1Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 8daratumumab 5Lenalidomide 5Bortezomib 5Thalidomide 4Cyclophosphamide 4carfilzomib 2Melphalan 2Calcium Dobesilate 2trametinib 1tanespimycin 1pomalidomide 1fludarabine 1dabrafenib 1cobimetinib 1Whole-Body Irradiation 1Vemurafenib 1Stem Cell Transplantation 1Rivaroxaban 1Mesna 1MAGEA3 protein, human 1Lenograstim 1Human Growth Hormone 1Hematopoietic Stem Cell Transplantation 1Granulocyte Colony-Stimulating Factor 1Etoposide 1Busulfan 1Bone Marrow Transplantation 1Aspirin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Multiple Myeloma × pomalidomide × Clear all
NCT06879379 2025-03-17

KPD Consolidation After ASCT in NDMM Patients

Peking University People's Hospital

Phase 2/3 Recruiting
202 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡